Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ezetimibe

- PMLiVE

Merck faces another Bridion knockback

It is seven years since the FDA initially rejected it

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

Merck rode out rival to sign $450m deal with NGM

Part of a five-year alliance on metabolic disorders and cancer

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

GSK squares up to Merck with shingles vaccine data

Trial shows vaccine cut the risk of shingles in over 50s by 97%

- PMLiVE

Merck stumps up $375m for cancer firm OncoEthix

Follows $8.4bn deal to buy Cubist

- PMLiVE

Merck names head of strategic communications

Julie Gerberding will also have responsibility for global public policy and population health

- PMLiVE

Merck’s ezetimibe has ‘modest’ benefit when added to statins

Combination showed a reduction in cardiovascular events in patients with ACS

- PMLiVE

Triple therapy ‘might cure hep C in six weeks’

Phase II trials shows promise for Merck and Gilead drugs

- PMLiVE

EMG appoints Merck and Boehringer directors as new officers

David Garmon-Jones is new chair and Zinta Krumins is vice chair

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links